Google
CRL 株価分析 — CHARLES RIVER LABORATORIES (Healthcare >> Diagnostics & Research)
CRL に関するよくある質問
CRLのPER（株価収益率）は？
CHARLES RIVER LABORATORIES（CRL）は現在PER 105.87倍で取引されています。
CRLのROE（自己資本利益率）は？
CHARLES RIVER LABORATORIESのROEは-6.28%です。
CRLの配当利回りは？
CHARLES RIVER LABORATORIESの配当利回りは0.00%です。
CRLの品質スコア（Quality Score）は？
当社のAIはCRLの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
CRLは今が買い時ですか？
当社AIのタイミングスコアは100点中87点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
CRLはどのセクターに属しますか？
CHARLES RIVER LABORATORIESはHealthcare >> Diagnostics & Researchセクターに分類されます（NYSE市場）
CRL AI Analysis Summary
Our AI summary for CRL: CHARLES RIVER LABORATORIES (NYSE), Healthcare >> Diagnostics & Research sector. The stock currently trades at a P/E of 105.87, ROE of -6.28%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 232.51
Price
-2.11
(-0.90%)
Day Change
|
|
|---|
CRL, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 232.51 |
| PBV / Sector |
3.78 / -29.69
|
| Earning Per Share | -3.80 |
| PE / Sector |
105.87 / 48.18
|
| PEG or PE/Growth / Sector |
-0.19 / 1.64
|
| Average 1M Daily Value |
156.09 M
GREAT
|
| Average 1W Daily Value |
173.55 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
58% |
| ポイントになる統計 |
|
54% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:40 |
| Symbol | CRL |
| Name | CHARLES RIVER LABORATORIES |
| Sector | Healthcare >> Diagnostics & Research |
| Market | NYSE |
| Listed Shares | 48.17 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 11,301.11 / 38,081.42 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 251 Ballardvale Street, Wilmington, MA, United States, 01887
Phone: 781 222 6000
Website: https://www.criver.com
Employees: 18,300
Description: Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Diagnostics & Research
Click a bubble to view stock details · Bubble size represents market capitalization share
